Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06393257
Other study ID # 20230901
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date May 2026

Study information

Verified date April 2024
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Jin-Fu Xu, PhD
Phone +8613321922898
Email jfxucn@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective randomized controlled trial is to explore the efficacy and safety of Oscillation and Lung Expansion-a airway clearance technology-in bronchiectasis. Participants will receive Oscillation and Lung Expansion or postural drainage randomly in this study. and the symptom, quality of life scores and amount of expectoration will be compared between the two groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date May 2026
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - patients with acute exacerbation of bronchiectasis Exclusion Criteria: - Haemoptysis greater than 50ml - state of endangerment - pneumothorax - Lung surgery history within 6 months - Severe heart, brain and nervous system diseases

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Oscillation and Lung Expansion
A novel airway clearance technology
Behavioral:
Postural drainage
A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.
Drug:
Anti-infective therapy
Antibiotics were used in these patients.
Mucolytic
Mucolytics were used in these patients.

Locations

Country Name City State
China Ruijin Hospital Shanghai Shanghai
China Shanghai pulmonary hospital Shanghai Shanghai
China The Shanghai First People's Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

References & Publications (7)

Basavaraj A, Choate R, Addrizzo-Harris D, Aksamit TR, Barker A, Daley CL, Anne Daniels ML, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL. Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest. 2020 Oct;158(4):1376-1384. doi: 10.1016/j.chest.2020.06.050. Epub 2020 Jul 3. — View Citation

Huynh TT, Liesching TN, Cereda M, Lei Y, Frazer MJ, Nahouraii MR, Diette GB. Efficacy of Oscillation and Lung Expansion in Reducing Postoperative Pulmonary Complication. J Am Coll Surg. 2019 Nov;229(5):458-466.e1. doi: 10.1016/j.jamcollsurg.2019.06.004. Epub 2019 Jul 27. — View Citation

Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2017 Sep 27;9(9):CD011699. doi: 10.1002/14651858.CD011699.pub2. — View Citation

Lin JL, Xu JF, Qu JM. Bronchiectasis in China. Ann Am Thorac Soc. 2016 May;13(5):609-16. doi: 10.1513/AnnalsATS.201511-740PS. — View Citation

Liu Y, Lu HW, Gu SY, Wang WW, Ge J, Jie ZJ, Jia JG, Gao ZT, Li J, Shi JY, Liang S, Cheng KB, Bai JW, Qu JM, Xu JF. Bronchoscopic airway clearance therapy for acute exacerbations of bronchiectasis. EBioMedicine. 2021 Oct;72:103587. doi: 10.1016/j.ebiom.2021.103587. Epub 2021 Sep 16. — View Citation

Munoz G, de Gracia J, Buxo M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur Respir J. 2018 Jan 11;51(1):1701926. doi: 10.1183/13993003.01926-2017. Print 2018 Jan. — View Citation

Zhou YM, Wang C, Yao WZ, Chen P, Kang J, Huang SG, Chen BY, Wang CZ, Ni DT, Liu SM, Wang XP, Wang DL, Lu JC, Zheng JP, Zhong NS, Ran PX. [The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China]. Zhonghua Nei Ke Za Zhi. 2013 May;52(5):379-82. Chinese. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary sputum volume in 24h 2 weeks
Secondary Bronchiectasis exacerbation and symptom tool BEST score Assessed at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks post-discharge
Secondary Quality of life questionnaire-bronchiectasis Qol-B score Assessed at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks post-discharge
Secondary Leicester Cough Questionnaire LCQ score Assessed at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks post-discharge
Secondary Bronchiectasis Health Questionnaire BHQ score Assessed at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks post-discharge
Secondary Time to the first bronchiectasis exacerbation since randomization Time to the first bronchiectasis exacerbation since randomization Assessed at 4 weeks, 8 weeks and 12 weeks post-discharge
See also
  Status Clinical Trial Phase
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Recruiting NCT06093191 - Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis Phase 4
Not yet recruiting NCT04509661 - Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation Phase 4
Recruiting NCT06017739 - Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Recruiting NCT03715322 - Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Phase 3
Recruiting NCT03696290 - Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Phase 2
Not yet recruiting NCT05068518 - The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
Recruiting NCT04658277 - Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations N/A
Completed NCT04744220 - Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis N/A
Completed NCT05764343 - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases N/A
Recruiting NCT05582798 - Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function Phase 4
Not yet recruiting NCT04987827 - Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
Recruiting NCT03791086 - The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Completed NCT04234789 - Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis N/A
Recruiting NCT04865861 - The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Completed NCT04742270 - Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis) N/A
Recruiting NCT05330637 - Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
Completed NCT05989360 - The Utility of Lung Clearance Index in Ethnic Groups and in Disease N/A
Completed NCT03125174 - Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls N/A